Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05312424 · ClinicalTrials.gov registry record · Phase 1
Annatto-derived GG for Statin-associated Myopathy
A Phase 1 study of Myopathy; Primary, sponsored by Texas Tech University Health Sciences Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 95
- Enrollment target
- 1
- Study location
NCT05312424 is a Phase 1 study of Myopathy; Primary that is actively recruiting participants, run by Texas Tech University Health Sciences Center. The registered enrollment target is 95 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05312424, a Phase 1 study of Myopathy; Primary, is actively recruiting participants, sponsored by Texas Tech University Health Sciences Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 95 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the effects of 3-months annatto-derived geranylgeraniol (GG) supplementation on statin-associated skeletal muscle health.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Low GG
- DIETARY_SUPPLEMENT High GG
Study Locations (1)
Texas
- Texas Tech University Health Sciences Center - Lubbock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2022-07-15 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05312424
The ClinicalTrials.gov registry entry for NCT05312424 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Texas Tech University Health Sciences Center, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myopathy; Primary appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05312424 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05312424 about?
NCT05312424 is a clinical study titled "Annatto-derived GG for Statin-associated Myopathy". To evaluate the effects of 3-months annatto-derived geranylgeraniol (GG) supplementation on statin-associated skeletal muscle health.
What is the current status of trial NCT05312424?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 95 participants. The study started on 2022-07-15. Estimated completion is 2027-12-31.
What conditions does trial NCT05312424 study?
This clinical trial studies the following conditions: Myopathy; Primary.
What interventions are being tested in trial NCT05312424?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Low GG (DIETARY_SUPPLEMENT), High GG (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05312424?
This trial is sponsored by Texas Tech University Health Sciences Center, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05312424 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.